bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Authors: Lambros Maryou B. , Seed George , Sumanasuriya Semini , Gil Veronica , Crespo Mateus , Fontes Mariane , Chandler Rob , Mehra Niven , Fowler Gemma , Ebbs Berni , Flohr Penny , Miranda Susana , Yuan Wei , Mackay Alan , Ferreira Ana , Pereira Rita , Bertan Claudia , Figueiredo Ines , Riisnaes Ruth , Rodrigues Daniel Nava , Sharp Adam , Goodall Jane , Boysen Gunther , Carreira Suzanne , Bianchini Diletta , Rescigno Pasquale , Zafeiriou Zafeiris , Hunt Joanne , Moloney Deirdre , Hamilton Lucy , Neves Rui P. , Swennenhuis Joost , Andree Kiki , Stoecklein Nikolas H. , Terstappen Leon W.M.M. , de Bono Johann S.
Published: April 2023

Summary of the validation steps. a) Male vs female: Genome plot of amplified male DNA vs amplified female DNA using the Ampli 1 kit. b) WBC vs WBC: Genomic profile of Ampli1 amplified WBCs against another WBC. c) Dilution evaluation: Genomic aberrations of an mCRPC sample with known CNA diluted serially to 10ng/ÂµL, 1ng/ÂµL, 0.1ng/ÂµL, and 0.03ng/ÂµL with all dilutions generating similar profiles after Ampli1TM WGA and aCGH. Gains and amplification depicted in blue, and losses and homozygous/deep deletion in red.
Figure S1 from MELK Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Guillén Navarro Miriam , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Angel , Bugiani Marianna , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

MELK mRNA expression during embryonic central nervous system development, derived from the Brainspan atlas.
Supplementary Figure S8 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Figure S8. A) FAO activity in BLCA cell lines upon CPTB overexpression. B) mRNA expression of ATP8B2 and PLA2G4C in patients with BLCA and BLCA cell lines of different grades. mRNA levels were normalized to GAPDH internal control.
Supplementary Table S1. ALFA-0701 - Adverse Events in Induction from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Authors: Jen Emily Y. , Ko Chia-Wen , Lee Jee Eun , Del Valle Pedro L. , Aydanian Antonina , Jewell Charles , Norsworthy Kelly J. , Przepiorka Donna , Nie Lei , Liu Jiang , Sheth Christopher M. , Shapiro Marjorie , Farrell Ann T. , Pazdur Richard
Published: April 2023

Supplemental Table 1 describes the adverse events with corresponding risk differences between treatment arms during induction of pivotal trial ALFA-0701.
Supplementary information from Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics
Authors: Yu Xin , Kogan Samuel , Chen Ying , Tsang Ashley T. , Withers Tracy , Lin Hongxia , Gilleran John , Buckley Brian , Moore Dirk , Bertino Joseph , Chan Chang , Kimball S. David , Loh Stewart N. , Carpizo Darren R.
Published: April 2023

Methods and figure legends
Table S 1, Figure S1, Figure S 2 from Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
Authors: Heck Matthias M. , Retz Margitta , Bandur Miriam , Souchay Marc , Vitzthum Elisabeth , Weirich Gregor , Schuster Tibor , Autenrieth Michael , Kübler Hubert , Maurer Tobias , Thalgott Mark , Herkommer Kathleen , Gschwend Jürgen E. , Nawroth Roman
Published: April 2023

Supplemental Table 1: A) Multivariable analysis for the association with biochemical recurrence comparing histopathologic and molecular lymph node status as categorical variables excluding 7 patients receiving adjuvant treatment for pN1-disease B) Multivariable analysis for the association with biochemical recurrence comparing histopathologic lymph node status and molecular maximum KLK3 expression in lymph nodes per patient as continuous variable excluding 7 patients receiving adjuvant treatment for pN1-disease Supplemental Figure 1: Distribution of the maximum KLK3 expression in lymph nodes per patient stratifying the study cohort in patients without lymph node metastases (pN0/molN0), patients with lymph node metastases detected exclusively by molecular analysis (pN0/molN1) or detected by both histopathologic and molecular analysis (pN1/molN1). Supplemental Figure 2: Biochemical recurrence-free survival according to lymph node status by (A) histopathology and (B) molecular analysis in a subgroup of 104 patients, who did not receive adjuvant treatment for pN1-status. Median biochemical recurrence-free survival was 3 months (95%CI 1.0-5.0) in 21 pN1-patients vs. not reached in 83 pN0-patients (p<0.001) and 18 months in 53 molN1-patients (95%CI 9.3-26.7) vs. not reached in 51 molN0-patients (p<0.001).
Supplementary table 2 from Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy
Authors: Panditharatna Eshini , Kilburn Lindsay B. , Aboian Mariam S. , Kambhampati Madhuri , Gordish-Dressman Heather , Magge Suresh N. , Gupta Nalin , Myseros John S. , Hwang Eugene I. , Kline Cassie , Crawford John R. , Warren Katherine E. , Cha Soonmee , Liang Winnie S. , Berens Michael E. , Packer Roger J. , Resnick Adam C. , Prados Michael , Mueller Sabine , Nazarian Javad
Published: April 2023

Midline glioma patient demographic information, and samples analyzed for genomic and ctDNA studies.
Supplementary Data from Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications
Authors: Rahman Rifaquat , Fell Geoffrey , Ventz Steffen , Arfé Andrea , Vanderbeek Alyssa M. , Trippa Lorenzo , Alexander Brian M.
Published: April 2023

Supplementary text, figures and tables
Supplementary Figure 4 from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Authors: Pailler Emma , Faugeroux Vincent , Oulhen Marianne , Mezquita Laura , Laporte Mélanie , Honoré Aurélie , Lecluse Yann , Queffelec Pauline , NgoCamus Maud , Nicotra Claudio , Remon Jordi , Lacroix Ludovic , Planchard David , Friboulet Luc , Besse Benjamin , Farace Françoise
Published: April 2023

Supplementary Figure 4
Supplementary Material from Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer–A Perspective on Future Trial Designs
Authors: Ventz Steffen , Trippa Lorenzo , Schoenfeld Jonathan D.
Published: April 2023

Supplementary Material Table S1: Operating characteristics. The Bayesian design conducts interim analyses for inferiority (using the probability of HR>1.2) every 1, 3, 6 or 12 months, starting from months 1, 3, 6 or 12. The far-right column reports operating characteristics for the RTOG 1016 protocol design. Table S2: Operating characteristics for a sample size N=860, which is larger than in RTOG 1016. Table S3: Operating characteristics (N=800). Table S4: Operating characteristics. The Bayesian design conducts interim analyses for inferiority every 1, 3, 6 or 12 months using the posterior probability of HR>1 for inferiority stopping. Results are based on 10,000 simulations using either a prior variance of 1/2, 1, 5 or 10. Outcome data of the control arm have been generated from reported Kaplan-Meier curves from RTOG 1016.
Supplementary Appendix from A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Authors: Lu Yen-Shen , Lee Keun Seok , Chao Tsu-Yi , Tseng Ling-Ming , Chitapanarux Imjai , Chen Shin-Cheh , Liu Chien-Ting , Sohn Joohyuk , Kim Jee Hyun , Chang Yuan-Ching , Yang Youngsen , Shotelersuk Kanjana , Jung Kyung Hae , Valenti Roberta , Slader Cassandra , Gao Melissa , Park Yeon Hee
Published: April 2023

Supplementary Appendix
Supplementary Data from Hypofractionated FLASH-RT as an Effective Treatment against Glioblastoma that Reduces Neurocognitive Side Effects in Mice
Authors: Montay-Gruel Pierre , Acharya Munjal M. , Gonçalves Jorge Patrik , Petit Benoît , Petridis Ioannis G. , Fuchs Philippe , Leavitt Ron , Petersson Kristoffer , Gondré Maude , Ollivier Jonathan , Moeckli Raphael , Bochud François , Bailat Claude , Bourhis Jean , Germond Jean-François , Limoli Charles L. , Vozenin Marie-Catherine
Published: April 2023

legend
Supplementary Tables S1_S2_S3_S5_S6 from Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Authors: Udayakumar Durga , Zhang Ze , Xi Yin , Dwivedi Durgesh K. , Fulkerson Michael , Haldeman Sydney , McKenzie Tiffani , Yousuf Qurratulain , Joyce Allison , Hajibeigi Asghar , Notgrass Hollis , de Leon Alberto Diaz , Yuan Qing , Lewis Matthew A. , Madhuranthakam Ananth J. , Sibley Robert C. , Elias Roy , Guo Junyu , Christie Alana , McKay Renée M. , Cadeddu Jeffrey A. , Bagrodia Aditya , Margulis Vitaly , Brugarolas James , Wang Tao , Kapur Payal , Pedrosa Ivan
Published: April 2023

Tables for ccRCC patient characteristics Gene expression log FC DCE 1st order statistics DCE-MRI vs. Signatures DCE-MRI vs. Vascular genes
Supplementary Table S7 from Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Authors: Udayakumar Durga , Zhang Ze , Xi Yin , Dwivedi Durgesh K. , Fulkerson Michael , Haldeman Sydney , McKenzie Tiffani , Yousuf Qurratulain , Joyce Allison , Hajibeigi Asghar , Notgrass Hollis , de Leon Alberto Diaz , Yuan Qing , Lewis Matthew A. , Madhuranthakam Ananth J. , Sibley Robert C. , Elias Roy , Guo Junyu , Christie Alana , McKay Renée M. , Cadeddu Jeffrey A. , Bagrodia Aditya , Margulis Vitaly , Brugarolas James , Wang Tao , Kapur Payal , Pedrosa Ivan
Published: April 2023

Metastatic cohort, RECIST 1.1, Hazard Ratio
Table S3 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Authors: Segal Neil H. , Cercek Andrea , Ku Geoffrey , Wu Abraham J. , Rimner Andreas , Khalil Danny N. , Reidy-Lagunes Diane , Cuaron John , Yang T. Jonathan , Weiser Martin R. , Romesser Paul B. , Stadler Zsofia K. , Varghese Anna M. , Ganesh Karuna , Yaeger Rona , Connell Louise C. , Faleck David , Abou-Alfa Ghassan K. , Mcauliffe Kathleen C. , Vaiskauskas Pamela , Solter Mark L. , Ogle Martinique , Adamow Matthew J. , Holland Aliya , Vedantam Pallavi , Wong Phillip , Merghoub Taha , Vakiani Efsevia , Hollmann Travis J. , Juluru Krishna , Chou Joanne F. , Capanu Marinela , Erinjeri Joseph , Solomon Stephen , Yamada Yoshiya , Kemeny Nancy , Crane Christopher H. , Saltz Leonard B.
Published: April 2023

Gene mutations in responder patients
Supplementary Figure S1 from Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer
Authors: Sztupinszki Zsofia , Diossy Miklos , Borcsok Judit , Prosz Aurel , Cornelius Nanna , Kjeldsen Maj K. , Mirza Mansoor R. , Szallasi Zoltan
Published: April 2023

Genomic scar scores, TCGA WES cohort
Supplementary Figure 5 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

Acino-ductal (AD) intermediate cells are cKit+ cells.
Table S1 from Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas
Authors: Corso Simona , Pietrantonio Filippo , Apicella Maria , Migliore Cristina , Conticelli Daniela , Petrelli Annalisa , D'Errico Laura , Durando Stefania , Moya-Rull Daniel , Bellomo Sara E. , Ughetto Stefano , Degiuli Maurizio , Reddavid Rossella , Fumagalli Uberto , De Pascale Stefano , Sgroi Giovanni , Rausa Emanuele , Baiocchi Gian Luca , Molfino Sarah , De Manzoni Giovanni , Bencivenga Maria , Siena Salvatore , Sartore-Bianchi Andrea , Morano Federica , Corallo Salvatore , Prisciandaro Michele , Di Bartolomeo Maria , Gloghini Annunziata , Marsoni Silvia , Sottile Antonino , Sapino Anna , Marchiò Caterina , Dahle-Smith Asa , Miedzybrodzka Zosia , Lee Jessica , Ali Siraj M. , Ross Jeffrey S. , Alexander Brian M. , Miller Vincent A. , Petty Russell , Schrock Alexa B. , Giordano Silvia
Published: April 2023

Supplementary Table 1
Supplementary Tables and Methods from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Authors: Crabb Simon J. , Danson Sarah , Catto James W.F. , Hussain Syed , Chan Danna , Dunkley Denise , Downs Nichola , Marwood Ellice , Day Laura , Saunders Geoff , Light Michelle , Whitehead Amy , Ellis Deborah , Sarwar Naveed , Enting Deborah , Birtle Alison , Johnson Bernadette , Huddart Robert , Griffiths Gareth
Published: April 2023

Supplementary Tables and Methods
Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Authors: Conforti Fabio , Pala Laura , Pagan Eleonora , Bagnardi Vincenzo , De Pas Tommaso , Queirolo Paola , Pennacchioli Elisabetta , Catania Chiara , Cocorocchio Emilia , Ferrucci Pier Francesco , Saponara Maristella , Orsolini Gianmarco , Zagami Paola , Nicoló Eleonora , De Marinis Filippo , Tortora Giampaolo , Bria Emilio , Minucci Saverio , Joffe Hadine , Veronesi Paolo , Wargo Jennifer , Rosenthal Rachel , Swanton Charles , Mantovani Alberto , Gelber Richard D. , Viale Giuseppe , Goldhirsch Aron , Giaccone Giuseppe
Published: April 2023

Supplementary Methods
Figure S2 from Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification
Authors: Lindgaard Sidsel C. , Sztupinszki Zsófia , Maag Emil , Chen Inna M. , Johansen Astrid Z. , Jensen Benny V. , Bojesen Stig E. , Nielsen Dorte L. , Hansen Carsten P. , Hasselby Jane P. , Nielsen Kaspar R. , Szallasi Zoltan , Johansen Julia S.
Published: April 2023

Supplementary figure S2 shows a Venn diagram of the proteins included in the two indices
Figure S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Authors: Sinn Bruno V. , Loibl Sibylle , Hanusch Claus A. , Zahm Dirk-Michael , Sinn Hans-Peter , Untch Michael , Weber Karsten , Karn Thomas , Becker Clemens , Marmé Frederik , Schmitt Wolfgang D. , Müller Volkmar , Schem Christian , Treue Denise , Stickeler Elmar , Klauschen Frederik , Burchardi Nicole , Furlanetto Jenny , van Mackelenbergh Marion , Fasching Peter A. , Schneeweiss Andreas , Denkert Carsten
Published: April 2023

Pre-treatment biopsy samples were available for all N = 174 patients. Of those, N = 162 could be successfully profiled by targeted RNA sequencing.
Supplementary Data from AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma
Authors: Reid Erin G. , Shimabukuro Kelly , Moore Page , Ambinder Richard F. , Bui Jack D. , Han Semi , Martínez-Maza Otoniel , Dittmer Dirk P. , Aboulafia David , Chiao Elizabeth Yu , Maurer Toby , Baiocchi Robert , Mitsuyasu Ronald , Wachsman William
Published: April 2023

Supplementary Data from AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma
Supplementary Results from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

Supplementary Results
Supplementary Data - Table 2 from A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)
Authors: Flaig Thomas W. , Tangen Catherine M. , Daneshmand Siamak , Alva Ajjai , Lerner Seth P. , Lucia M. Scott , McConkey David J. , Theodorescu Dan , Goldkorn Amir , Milowsky Matthew I. , Bangs Rick , MacVicar Gary R. , Bastos Bruno R. , Fowles Jared S. , Gustafson Daniel L. , Plets Melissa , Thompson Ian M.
Published: April 2023

Supplemental Table 2. Comparing GC and DDMVAC for Pathologic Response at Cystectomy - intention to treat analysis
Figure S3 from TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Authors: Kawazoe Akihito , Itahashi Kota , Yamamoto Noboru , Kotani Daisuke , Kuboki Yasutoshi , Taniguchi Hiroya , Harano Kenichi , Naito Yoichi , Suzuki Mitsuko , Fukutani Miki , Higuchi Tsukiko , Ikeno Takashi , Wakabayashi Masashi , Sato Akihiro , Koyama Shohei , Nishikawa Hiroyoshi , Shitara Kohei
Published: April 2023

Figure S3
Supplementary Information from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Authors: Yu Alice L. , Gilman Andrew L. , Ozkaynak M. Fevzi , Naranjo Arlene , Diccianni Mitchell B. , Gan Jacek , Hank Jacquelyn A. , Batova Ayse , London Wendy B. , Tenney Sheena C. , Smith Malcolm , Shulkin Barry L. , Parisi Marguerite , Matthay Katherine K. , Cohn Susan L. , Maris John M. , Bagatell Rochelle , Park Julie R. , Sondel Paul M.
Published: April 2023

Figure S1a, Figure S1b; Supplementary Tables S1-S7
Supplementary Figures from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Authors: Kelly Gregory M. , Al-Ejeh Fares , McCuaig Robert , Casciello Francesco , Ahmad Kamal Nabilah , Ferguson Blake , Pritchard Antonia L. , Ali Sayed , Silva Ines P. , Wilmott James S. , Long Georgina V. , Scolyer Richard A. , Rao Sudha , Hayward Nicholas K. , Gannon Frank , Lee Jason S.
Published: April 2023

Supplementary Figures
Table S1 from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Table S1
Supplementary Table 4 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Authors: Even Caroline , Wang Hung-Ming , Li Shau-Hsuan , Ngan Roger K-C , Dechaphunkul Arunee , Zhang Li , Yen Chia-Jui , Chan Po Chung , Chakrabandhu Somvilai , Ma Brigette B.Y. , Tanasanvimon Suebpong , Lee Victor H.F. , Lou Pei-Jen , Li Zujun , Spira Alexander I. , Sukari Ammar , Guigay Joël , McCune Steven , Gonzalez-Maffe Juan , Szpakowski Sebastian , Yao Yao , Liang Hongzi , Mataraza Jennifer , Séchaud Romain , Manenti Luigi , Lim Darren W-T.
Published: April 2023

Supplemental Table S4. Post-treatment antineoplastic medication
Supplementary Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Authors: van Putten Erik H.P. , Kleijn Anne , van Beusechem Victor W. , Noske David , Lamers Cor H.J. , de Goede Anna L. , Idema Sander , Hoefnagel Daphna , Kloezeman Jenneke J. , Fueyo Juan , Lang Frederick F. , Teunissen Charlotte E. , Vernhout René M. , Bakker Cathy , Gerritsen Winald , Curiel David T. , Vulto Arnold , Lamfers Martine L.M. , Dirven Clemens M.F.
Published: April 2023

Supplementary Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
Supplementary Data from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Authors: Zhu Mojun , Chen Chunhua , Foster Nathan R. , Hartley Christopher , Mounajjed Taofic , Salomao Marcela A. , Fruth Briant F. , Beamer Staci E. , Kim Yohan , Harrington Susan M. , Pitot Henry C. , Sanhueza Cristobal T. , Feng Yening , Herrmann Joerg , McWilliams Robert R. , Lucien Fabrice , Huang Bing Q. , Ma Wen Wee , Bekaii-Saab Tanios S. , Dong Haidong , Wigle Dennis , Ahn Daniel H. , Hallemeier Chris L. , Blackmon Shanda , Yoon Harry H.
Published: April 2023

Supplementary Data from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Supplementary Figure from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Authors: Fendler Wolfgang P. , Pabst Kim M. , Kessler Lukas , Fragoso Costa Pedro , Ferdinandus Justin , Weber Manuel , Lippert Maria , Lueckerath Katharina , Umutlu Lale , Kostbade Karina , Mavroeidi Ilektra A. , Schuler Martin , Ahrens Marit , Rischpler Christoph , Bauer Sebastian , Herrmann Ken , Siveke Jens T. , Hamacher Rainer
Published: April 2023

Supplementary Figure from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Supplementary Table from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models
Authors: Li Fuyang , Bondra Kathryn M. , Ghilu Samson , Studebaker Adam , Liu Qianqian , Michalek Joel E. , Kogiso Mari , Li Xiao-Nan , Kalapurakal John A. , James C. David , Burma Sandeep , Kurmasheva Raushan T. , Houghton Peter J.
Published: April 2023

Supplementary Table from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models
Supplementary Data from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Authors: Palazón-Carrión Natalia , Martín García-Sancho Alejandro , Nogales-Fernández Esteban , Jiménez-Cortegana Carlos , Carnicero-González Fernando , Ríos-Herranz Eduardo , de la Cruz-Vicente Fátima , Rodríguez-García Guillermo , Fernández-Álvarez Rubén , Martínez-Banaclocha Natividad , Gumà-Padrò Josep , Gómez-Codina José , Salar-Silvestre Antonio , Rodríguez-Abreu Delvys , Gálvez-Carvajal Laura , Labrador Jorge , Guirado-Risueño María , García-Domínguez Daniel J. , Hontecillas-Prieto Lourdes , Espejo-García Pablo , Fernández-Román Isabel , Provencio-Pulla Mariano , Sánchez-Beato Margarita , Navarro Marta , Marylene Lejeune , Álvaro-Naranjo Tomás , Casanova-Espinosa Maria , Sánchez-Margalet Victor , Rueda-Domínguez Antonio , de la Cruz-Merino Luis
Published: April 2023

Supplementary Data from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Supplementary Data from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Authors: Markowski Mark C. , Tutrone Ronald , Pieczonka Christopher , Barnette K. Gary , Getzenberg Robert H. , Rodriguez Domingo , Steiner Mitchell S. , Saltzstein Daniel R. , Eisenberger Mario A. , Antonarakis Emmanuel S.
Published: April 2023

Supplementary Data from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Supplementary Data from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
Authors: Szabados Bernadett , Ponz-Sarvisé Mariano , Machado Robson , Saldana Diego , Kadel Edward E. , Banchereau Romain , Bouquet Fanny , Garmhausen Marius , Powles Thomas , Schröder Carsten
Published: April 2023

Supplementary Data from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Aggarwal Rahul , Starodub Alexander N. , Koh Brian D. , Xing Guan , Armstrong Andrew J. , Carducci Michael A.
Published: April 2023

Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Supplementary Data from Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers
Authors: Gazinska Patrycja , Milton Charlotte , Iacovacci Jacopo , Ward Joseph , Buus Richard , Alaguthurai Thanussuyah , Graham Rosalind , Akarca Ayse , Lips Esther , Naidoo Kalnisha , Wesseling Jelle , Marafioti Teresa , Cheang Maggie , Gillett Cheryl , Wu Yin , Khan Aadil , Melcher Alan , Salgado Roberto , Dowsett Mitch , Tutt Andrew , Roxanis Ioannis , Haider Syed , Irshad Sheeba
Published: April 2023

Supplementary Data from Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers
Supplementary Figure S4 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Effect of trametinib and ganitumab in additional cell culture models of RAS-mutated RMS
Supplementary Table from OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma
Authors: Xu Zhenhua , Murad Najiba , Malawsky Daniel , Tao Ran , Rivero-Hinojosa Samuel , Holdhof Dörthe , Schüller Ulrich , Zhang Peng , Lazarski Christopher , Rood Brian R. , Packer Roger , Gershon Timothy , Pei Yanxin
Published: April 2023

Supplementary Table from OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma
Supplementary Tables 1-2 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
Authors: Ge Huaibin , Ferris Robert L. , Wang Jing H.
Published: April 2023

Supplementary Table 1-2
Supplementary Figure 6 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Authors: Sathe Anuja , Mason Kaishu , Grimes Susan M. , Zhou Zilu , Lau Billy T. , Bai Xiangqi , Su Andrew , Tan Xiao , Lee HoJoon , Suarez Carlos J. , Nguyen Quan , Poultsides George , Zhang Nancy R. , Ji Hanlee P.
Published: April 2023

(A-C) Comparisons with Pearson correlation between (A) proportions of cell lineages in five samples with both scRNA-seq and CODEX data. (B) Average expression of LGALS3 and CD68 in macrophages across all 15 patients. (C) Average expression of COL4A1 and ACTA2 in CAFs across all 15 patients.
Supplementary Figure 3 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Authors: Sathe Anuja , Mason Kaishu , Grimes Susan M. , Zhou Zilu , Lau Billy T. , Bai Xiangqi , Su Andrew , Tan Xiao , Lee HoJoon , Suarez Carlos J. , Nguyen Quan , Poultsides George , Zhang Nancy R. , Ji Hanlee P.
Published: April 2023

(A) UMAP representation of dimensionally reduced data following batch-corrected graph-based clustering of all lymphocyte lineage cells annotated by cell types. (B) Heatmap depicting average expression of selected genes for each cell type. (C) UMAP representation annotated by condition. (D) Heatmap depicting cell states from CD8 T cells identified using EcoTyper NMF analysis, annotated by condition. (A-D) Data from seven mCRCs, five paired normal liver tissue and two paired PBMCs. (E) Violin plot depicting the expression of cytotoxicity gene signature in normal and tumor CD8 T cells with T-test p-value. Data from seven mCRCs, five paired normal liver tissue.
Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

Vaccinated D-neopeptides activate tumor-infiltrating antitumor T cells. (A) Circos plots provide an overview of the frequencies of Vβ-Jβ pairing in the primary and recurrent tumors. (B) Surface TCR β chain expression of the D-neopeptide-specific CD4+ TCCs was analyzed using FACs.
Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

TILs do not respond to N-class I-peptides. TILs were stimulated with 5- or 10 μM N-class I-peptides for 5 days. 5 replicate wells were tested for proliferation, and proliferation was measured by 3H-thymidine incorporation assay. The proliferation strength is depicted as SI. (#) indicates the peptide that was used in the 1st to 4th vaccinations. Data are expressed as mean ± SEM.
Supplementary Data from STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer
Authors: Qureshy Zoya , Li Hua , Zeng Yan , Rivera Jose , Cheng Ning , Peterson Christopher N. , Kim Mi-Ok , Ryan William R. , Ha Patrick K. , Bauman Julie E. , Wang Steven J. , Long Steven R. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

Supplementary Data from STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer
Supplementary Table S3 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
Authors: Peng Ke , Zhang Feifei , Wang Yichen , Sahgal Pranshu , Li Tianxia , Zhou Jin , Liang Xiaoyan , Zhang Yanxi , Sethi Nilay , Liu Tianshu , Zhang Haisheng , Bass Adam J.
Published: April 2023

Z Scores from ORF screen
Supplementary Figure S5 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Authors: Asleh Karama , Lluch Ana , Goytain Angela , Barrios Carlos , Wang Xue Q. , Torrecillas Laura , Gao Dongxia , Ruiz-Borrego Manuel , Leung Samuel , Bines José , Guerrero-Zotano Ángel , García-Sáenz Jose Ángel , Cejalvo Juan Miguel , Herranz Jesus , Torres Roberto , Haba-Rodriguez Juan de la , Ayala Francisco , Gómez Henry , Rojo Federico , Nielsen Torsten O. , Martin Miguel
Published: April 2023

Supplementary Figure S5 shows a forest plot of the exploratory categorical analysis of selected (meta)gene expression and their association with overall survival on the capecitabine arm vs. observation.
Supplementary Figure S1 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Authors: Asleh Karama , Lluch Ana , Goytain Angela , Barrios Carlos , Wang Xue Q. , Torrecillas Laura , Gao Dongxia , Ruiz-Borrego Manuel , Leung Samuel , Bines José , Guerrero-Zotano Ángel , García-Sáenz Jose Ángel , Cejalvo Juan Miguel , Herranz Jesus , Torres Roberto , Haba-Rodriguez Juan de la , Ayala Francisco , Gómez Henry , Rojo Federico , Nielsen Torsten O. , Martin Miguel
Published: April 2023

Supplementary Figure S1 shows the expression of the 50 genes in the PAM50 signature, obtained from the 164-gene codeset.
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Authors: Kebir Sied , Ullrich Vivien , Berger Pia , Dobersalske Celia , Langer Sarah , Rauschenbach Laurèl , Trageser Daniel , Till Andreas , Lorbeer Franziska K. , Wieland Anja , Wilhelm-Buchstab Timo , Ahmad Ashar , Fröhlich Holger , Cima Igor , Prasad Shruthi , Matschke Johann , Jendrossek Verena , Remke Marc , Grüner Barbara M. , Roesch Alexander , Siveke Jens T. , Herold-Mende Christel , Blau Tobias , Keyvani Kathy , van Landeghem Frank K.H. , Pietsch Torsten , Felsberg Jörg , Reifenberger Guido , Weller Michael , Sure Ulrich , Brüstle Oliver , Simon Matthias , Glas Martin , Scheffler Björn
Published: April 2023

Extended Data relating to Main Figure 2/Assessment of ALDH1A1+ cells from primary, treatment-naive glioblastoma. A, Bar plot shows ALDH-bright (ALDHbr) vital cells from two additional paired cases of naive vs. experimental (TMZ→eR) and clinical (cR) relapse. Data as mean ± SD. p values by one-way analysis of variance (ANOVA) with Tukey´s post-hoc test. B, Dotplot shows ALDH1A1 mean fluorescence intensity (MFI) in paired BN46 treatment-naive vs. experimental relapse conditions (in vitro exposure to TMZ (TMZ→eR) or irradiation (RT→eR)). Data are normalized to isotype control, mean ± SD. p values calculated by Kruskal-Wallis test with Dunn's post-hoc test. C, Relative ALDH1A1 expression in -knockdown (shALDH1A1) and -overexpression (Ovx) BN46 cells used for indicated experiment. Data shown as mean ± SD, normalized to their respective controls (ALDH1A1 Ovx to GFP Ctrl | shALDH1A1 to shNT Ctrl). D, Left: Brightfield image of BN46 cells in 96-well plates during monitoring by software-based cell recognition in the limiting dilution assay (NyOne®). An exemplary single cell/well is shown at one day post seeding; representative monoclonal colonies of ALDH1A1-knockdown (sh) and -overexpressing (Ovx) cells at day 16 after seeding. Right: Doubling time estimated at day 16 after seeding (see Methods). Data as mean ± SD, p values calculated by Kruskal-Wallis test with Dunn's post-hoc test. E, Left: Cartoon describes the neurosphere experiments shown in Fig. 2H. Right: Phase contrast microscopic appearance of plated 2° neurosphere and respective immunofluorescence visualization of antibody labeling on neurosphere-derived cells. Neuronal phenotype, β3-tubulin (β3-tub); glial phenotypes, glial fibrillary acidic protein (GFAP). Nuclei exposed with DAPI. Scale bars: left: 100 µM, right: 50 µM. F, Table showing quantification data of 1° and 2° neurosphere generations from (E) in the respective treatment-naive BN46 cells. G, All plated 2° neurospheres from assay (E,F) generated neuronal and glial cell phenotypes.
Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Authors: Banerjee Susana , Michalarea Vasiliki , Ang Joo Ern , Ingles Garces Alvaro , Biondo Andrea , Funingana Ionut-Gabriel , Little Martin , Ruddle Ruth , Raynaud Florence , Riisnaes Ruth , Gurel Bora , Chua Sue , Tunariu Nina , Porter Joanna C. , Prout Toby , Parmar Mona , Zachariou Anna , Turner Alison , Jenkins Ben , McIntosh Stuart , Ainscow Ed , Minchom Anna , Lopez Juanita , de Bono Johann , Jones Robert , Hall Emma , Cook Natalie , Basu Bristi , Banerji Udai
Published: April 2023

Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Figure S3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

Supplemental Figure S3. Sample partitioning for training and testing a RAS pathway mutation predictive model using K-fold cross-validation. Three independent experiments were trained on a random selection of samples for training, validation and testing.
Figure S1 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

Supplemental Figure S1. Performance of A.I. model in classifying multiple samples from the same patient.
Supplementary Data 4 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Authors: Gopal Priyanka , Yard Brian D. , Petty Aaron , Lal Jessica C. , Bera Titas K. , Hoang Trung Q. , Buhimschi Alexandru D. , Abazeed Mohamed E.
Published: April 2023

Supplementary Data 4: ssGSEA and survival after irradiation
Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
Authors: Matsubara Nobuaki , de Bono Johann , Olmos David , Procopio Giuseppe , Kawakami Satoru , Ürün Yüksel , van Alphen Robbert , Flechon Aude , Carducci Michael A. , Choi Young Deuk , Hotte Sebastien J. , Korbenfeld Ernesto , Kramer Gero , Agarwal Neeraj , Chi Kim N. , Dearden Simon , Gresty Christopher , Kang Jinyu , Poehlein Christian , Harrington Elizabeth A. , Hussain Maha
Published: April 2023

Supplementary data presenting additional demographic data and safety analysis.
Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Authors: Giraldo Nicolas A. , Drill Esther , Satravada Baby A. , Dika Imane El , Brannon A. Rose , Dermawan Josephine , Mohanty Abhinita , Ozcan Kerem , Chakravarty Debyani , Benayed Ryma , Vakiani Efsevia , Abou-Alfa Ghassan K. , Kundra Ritika , Schultz Nikolaus , Li Bob T. , Berger Michael F. , Harding James J. , Ladanyi Marc , O'Reilly Eileen M. , Jarnagin William , Vanderbilt Chad , Basturk Olca , Arcila Maria E.
Published: April 2023

Detailed statistical results
Supplementary Table from Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Authors: Nagler Arnon , Ngoya Maud , Galimard Jacques-Emmanuel , Labopin Myriam , Bornhäuser Martin , Stelljes Matthias , Finke Jürgen , Ganser Arnold , Einsele Herman , Kröger Nicolaus , Brecht Arne , Bethge Wolfgang , Edinger Matthias , Kulagin Aleksandr , Passweg Jakob , Blau Igor Wolfgang , Elmaagacli Ahmet , Schäfer-Eckart Kerstin , Platzbecker Uwe , Schroeder Thomas , Bunjes Donald , Tischer Johanna , Martin Sonja , Spyridonidis Alexandros , Giebel Sebastian , Savani Bipin , Mohty Mohamad
Published: April 2023

Supplementary Table from Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Authors: Giraldo Nicolas A. , Drill Esther , Satravada Baby A. , Dika Imane El , Brannon A. Rose , Dermawan Josephine , Mohanty Abhinita , Ozcan Kerem , Chakravarty Debyani , Benayed Ryma , Vakiani Efsevia , Abou-Alfa Ghassan K. , Kundra Ritika , Schultz Nikolaus , Li Bob T. , Berger Michael F. , Harding James J. , Ladanyi Marc , O'Reilly Eileen M. , Jarnagin William , Vanderbilt Chad , Basturk Olca , Arcila Maria E.
Published: April 2023

Table S2. Oncogenic/Likely-oncogenic structural variants in GBC
Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

Proposed treatment strategy for MET-driven acquired resistance to EGFR TKI in EGFR-mutant NSCLC patients.
Supplementary Figure from Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
Authors: Febres-Aldana Christopher A. , Chang Jason C. , Ptashkin Ryan , Wang Yuhan , Gedvilaite Erika , Baine Marina K. , Travis William D. , Ventura Katia , Bodd Francis , Yu Helena A. , Quintanal-Villalonga Alvaro , Lai W. Victoria , Egger Jacklynn V. , Offin Michael , Ladanyi Marc , Rudin Charles M. , Rekhtman Natasha
Published: April 2023

Supplementary Figure from Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
Supplementary Table 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
Authors: Mierzwa Michelle L. , Aryal Madhava , Lee Choonik , Schipper Matthew , VanTil Monica , Morales Krystal , Swiecicki Paul L. , Casper Keith A. , Malloy Kelly M. , Spector Matthew E. , Shuman Andrew G. , Chinn Steven B. , Prince Mark E.P. , Stucken Chaz L. , Rosko Andrew J. , Lawrence Theodore S. , Brenner J. Chad , Rosen Benjamin , Schonewolf Caitlin A. , Shah Jennifer , Eisbruch Avraham , Worden Francis P. , Cao Yue
Published: April 2023

LAHNSCC patients by treatment site and stage
Table S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Authors: Ma Yuanqing , Joyce Allison , Brandenburg Olivia , Saatchi Faeze , Stevens Christina , Toffessi Tcheuyap Vanina , Christie Alana , Do Quyen N. , Fatunde Oluwatomilade , Macchiaroli Alyssa , Wong So C. , Woolford Layton , Yousuf Qurratulain , Miyata Jeffrey , Carrillo Deyssy , Onabolu Oreoluwa , McKenzie Tiffani , Mishra Akhilesh , Hardy Tanner , He Wei , Li Daniel , Ivanishev Alexander , Zhang Qing , Pedrosa Ivan , Kapur Payal , Schluep Thomas , Kanner Steven B. , Hamilton James , Brugarolas James
Published: April 2023

Table S2
Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Authors: Chen Tom Wei-Wu , Hsu Chia-Lang , Hong Ruey-Long , Lee Jen-Chieh , Chang Koping , Yu Chih-Wei , Chen San-Chi , Guo Jhe-Cyuan , Chen Mei-Lu , Hsu Meng-Chi , Kung Ting-Fang , Cheng Ann-Lii , Yen Chueh-Chuan
Published: April 2023

Cell type predictive of treatment efficacy. Cell type differences of (a) partial response vs non-partial responders (b) progression-free survival longer vs shorter than 6 months by MCP-Counter. All p-values were derived from non-parametric Wilcoxon test.
Supplementary Figure S1 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Authors: Mishra Akhilesh , Kumar Dhiraj , Gupta Kuldeep , Lofland Gabriela , Sharma Ajay Kumar , Banka Dhanush S. , Hobbs Robert F. , Dannals Robert F. , Rowe Steven P. , Gabrielson Edward , Nimmagadda Sridhar
Published: April 2023

A, Synthesis of DK223. B, RP-HPLC chromatogram of DK223.
Supplementary Figure S2 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Authors: O'Connell Casey L. , Baer Maria R. , Ørskov Andreas Due , Saini Sunil Kumar , Duong Vu H. , Kropf Patricia , Hansen Jakob Werner , Tsao-Wei Denice , Jang Hyo Sik , Emadi Ashkan , Holmberg-Thyden Staffan , Cowland Jack , Brinker Brett T. , Horwood Kristin , Burgos Ryan , Hostetter Galen , Youngblood Benjamin A. , Hadrup Sine Reker , Issa Jean-Pierre , Jones Peter , Baylin Stephen B. , Siddiqi Imran , Grønbaek Kirsten
Published: April 2023

A. Gating strategy applied on PBMCs samples evaluated by flow cytometry. CD8+ T cell memory was defined based on the expression of CD45RA and CCR7 (CD197). Cell surface phenotype (PD-1, CD39, and CD69) and intracellular activation (Ki-67) markers were quantified on CD8+ effector T cell (TEFF) based on indicated gates. B, CD8+ naïve and memory T cells in long-and short-survivors quantified before and after the treatment. C, Representative flow cytometry plots showing CD8+ T cells activation in PBMC samples from a short survivor. PD-1+ Ki-67+ expression on CD8+ T cells compared before and after the treatment.
Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Authors: Constantinidou Anastasia , Marcou Yiola , Toss Michael S. , Simmons Timothy , Bernhisel Ryan , Hughes Elisha , Probst Braden , Meek Stephanie , Kakouri Eleni , Georgiou Georgios , Zouvani Ioanna , Savvidou Gabriella , Kuhl Vanessa , Doedt Jennifer , Wagner Susanne , Gutin Alexander , Slavin Thomas P. , Lanchbury Jerry S. , Kronenwett Ralf , Ellis Ian O. , Rakha Emad A.
Published: April 2023

Supplementary Data from Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Supplementary Table S4 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Authors: Zhou Yan , Yang Qingcheng , Dong Yang , Ji Tong , Zhang Bing , Yang Cheng , Zheng Shuier , Tang Lina , Zhou Chenliang , Qian Guowei , Huang Yujing , Yu Wenxi , Li Hongtao , Wang Yonggang , He Aina , Shen Zan , Bao Qiyuan , Hua Yingqi , Bai Hongyu , Zhao Jiayi , Li Xiaoyi , Dai Xiangrong , Zhang Jianjun , Hu Haiyan , Yao Yang
Published: April 2023

Pharmacokinetic parameters after multiple administration